ICID 2020
20-23 February 2019
Kuala Lumpur, Malaysia
- DNDi is a collaborative organization
PAHO secures significant price reductions for hepatitis C medicines
The Pan-American Health Organization (PAHO) has succeeded in reducing the price of expensive medicines that can cure people living with hepatitis C (HCV), according to an announcement made at its 57th Directing Council meeting. PAHO has negotiated prices of US$129 for 3 months of treatment from generic sources of sofosbuvir/daclatasvir. This significant a move could enable national programmes to scale up diagnosis and treatment and eliminate HCV as a public health problem.
A four-step process for building sustainable access to diagnosis and treatment of Chagas disease
by Batista C, Forsyth CJ, Herazo R, Certo MP, Marchiol A.
Pan American Journal of Public Health, September 2019
Lack of awareness of Chagas disease in the US leading to unnecessary deaths in vulnerable immigrant communities
New York/Los Angeles – 26 September 2019
New DNDi/CECD/MSF paper published in PLOS Neglected Tropical Diseases on the “silent killer” Chagas disease
Fear, stigma, gaps in the health system, and lack of awareness in the medical community are among the barriers keeping the most vulnerable from accessing essential care for Chagas disease, a leading cause of heart disease in the Americas, according to a paper published today by the not-for-profit drug development organization DNDi, the Center of Excellence for Chagas Disease, and the international medical humanitarian organization MSF.
La falta de concientización sobre la enfermedad de Chagas en los EEUU está causando muertes prevenibles en comunidades de inmigrantes vulnerables
Nueva York/Los Ángeles – 26 September 2019
Nuevo artículo de DNDi/CECD/MSF publicado en PLOS Neglected Tropical Diseases sobre la enfermedad de Chagas, “el asesino silencioso”.
El miedo, las brechas en el sistema de salud y la falta de concientización son algunas de las barreras que impiden el acceso de los más vulnerables al tratamiento de la enfermedad de Chagas, una de las principales causas de problemas cardíacos en las Américas, según un artículo publicado por la organización sin fines de lucro de desarrollo de medicamentos iniciativa Medicamentos para Enfermedades Olvidadas (DNDi, por su acrónimo en inglés), el Center of Excellence for Chagas Disease (CECD) del centro médico Olive View de la UCLA y la organización humanitaria médica internacional Médicos Sin Fronteras (MSF).
Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States
by Forsyth C, Meymandi S, Moss I, Cone J, Cohen R, Batista C.
PLOS Neglected Tropical Diseases, September 2019
Innovations for the elimination and control of visceral leishmaniasis
by Selvapandiyan A, Croft SL, Rijal S, Nakhasi HL, Ganguly NK.
PLOS Neglected Tropical Diseases, September 2019
Comparative evaluation of immunoassays to improve access to diagnosis for Chagas disease in Colombia
by Caicedo Díaz RA, Forsyth C, Bernal OA, Marchiol A, Beltrán Duran M, Batista C, Herazo R, Vera MJ, Pachon E, Valencia-Hernández CA, Flórez Sánchez AF.
International Journal of Infectious Diseases, July 2019
Kempen Saringan Hepatitis C Seluruh Negara Anjuran Kementerian Kesihatan Malaysia
Kuala Lumpur – 17 Julai 2019
Kempen disokong oleh Drugs for Neglected Diseases initiative (DNDi) dan Foundation for Innovative New Diagnostics (FIND), bertujuan untuk mengesan pesakit yang menghidap HCV, iaitu sejenis penyakit yang senyap namun ianya boleh dirawat secara berkesan
‘Foundation for Innovative New Diagnostics’ (FIND) dan ‘Drugs for Neglected Diseases initiative’ (DNDi) sedang bekerjasama dengan Kementerian Kesihatan Malaysia (KKM) bagi melancarkan inisiatif terbesar di seluruh negara dalam usaha penyaringan virus hepatitis C (HCV).
马来西亚卫生部发起全国性C型肝炎检验活动
（吉隆坡17日讯）
在“被忽视疾病药物研发倡议组织”（DNDi)和创新诊断基金会(FIND)的支持下，该活动在为这种无声但可治愈的疾病寻找“遗漏的数百万人”
创新诊断基金会（FIND）和被忽视疾病药物倡议组织（DNDi）正与马来西亚卫生部（MOH）合作，推出我国有史以来规模最大的C型肝炎病毒筛查计划。
การรณรงค์คัดกรองไวรัสตับอักเสบซีทั่วประเทศ โดยกระทรวงสาธารณสุขมาเลเซีย
กัวลาลัมเปอร์ – 17 กรกฎาคม 2562
สนับสนุนโดยองค์กรยารักษาโรคที่ถูกละเลยและมูลนิธิเพื่อการวินิจฉัยเชิงนวัตกรรมใหม่ การรณรงค์เพื่อค้นหา “ผู้สูญหายนับล้าน” สำหรับภัยเงียบจากโรคที่รักษาได้
มูลนิธิเพื่อการวินิจฉัยเชิงนวัตกรรมใหม่ (The Foundation for Innovative New Diagnostics -FIND) และองค์กรยาเพื่อรักษาโรคที่ถูกละเลย (Drugs for Neglected Diseases initiative – DNDi) ร่วมกับกระทรวงสาธารณสุขประเทศมาเลเซีย (MOH) เพื่อเปิดตัวโครงการคัดกรองไวรัสตับอักเสบซี (HCV) ที่ใหญ่ที่สุดในประเทศ
Nationwide hepatitis C screening campaign initiated by the Malaysian Ministry of Health
Kuala Lumpur – 17 July 2019
Supported by Drugs for Neglected Diseases initiative & Foundation for Innovative New Diagnostics, campaign seeks to find the “missing millions” for this silent but curable disease
FIND and DNDi are partnering with the Ministry of Health in Malaysia to launch the country’s biggest-ever screening initiative for the hepatitis C virus.
Utusan Borneo [16 July 2019]
“Saringan Hepatitis secara besar-besaran dan percuma” – “Massive and free screening of hepatitis”
Bernama [15 July 2019]
“Nationwide free hepatitis C screening campaign”
WHO adds first all-oral sleeping sickness drug to Essential Medicines List
Fexinidazole, the first all-oral treatment for sleeping sickness registered by Sanofi and developed in clinical trials led by DNDi, has been added to the World Health Organization’s Essential Medicines Lists for adults and children, for the treatment of both stages of the disease.
Health Policy Watch [9 July 2019]
“New cancer drugs top entries on WHO Essential Medicines List”
DNDi receives 1 billion yen from Takeda to improve access to treatment for neglected patients
DNDi is pleased to announce a new partnership with Takeda Pharmaceutical Company Limited whose multi-year commitment was made through Takeda employees’ voting for Global Corporate Social Responsibility (CSR) Program 2019.